An aminomethylpyrimidine DPP-IV inhibitor with improved properties

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 13, 2004, Pages 3575-3578

  Peters, Jens Uwe ^a   Hunziker, Daniel ^a   Fischer, Holger ^a   Kansy, Manfred ^a   Weber, Silja ^a   Kritter, Stéphane ^a   Müller, Aranka ^a   Wallier, Angelina ^a   Ricklin, Fabienne ^a   Boehringer, Markus ^a   Poli, Sonia Maria ^a   Csato, Miklos ^a   Loeffler, Bernd Michael ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOMETHYLPYRIMIDINE; CYTOCHROME P450 3A4; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; LIPIDOSIS; LIPOPHILICITY; PHYSICAL CHEMISTRY;

AMINES; ANTIGENS, CD26; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INHIBITORY CONCENTRATION 50; LIPIDOSES; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; PYRIMIDINES;

EID: 2942624254     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.04.048     Document Type: Article

References (31)

1. For reviews, see: Drucker D.J. Diabetes Care. 26:2003;2929
2. Augustyns K., Van der Veken P., Senten K., Haerners A. Exp. Opin. Ther. Patents. 13:2003;499
3. For a review, see: Holst J.J., Orskov C. Scand. J. Clin. Lab. Invest. 61(Suppl. 234):2001;75
4. Rachman J., Barrow B.A., Levy J.C., Turner R.C. Diabetologica. 40:1997;205
5. Nauck M.A., Wollschlager D., Werner J., Holst J.J., Orskov C., Creutzfeldt W. Diabetologica. 39:1996;1546
6. Knudsen L.B., Pridal L. Eur. J. Pharmacol. 318:1996;429
7. For a review, see: Rosenblum J.S., Kozarich J.W. Curr. Opin. Chem. Biol. 7:2003;496
8. Pauly R.P., Demuth H.U., Rosche F., Schmidt J., White H.A., Lynn F., McIntosh C.H., Pederson R.A. Metab.: Clin. Exp. 48:1999;385
9. For a review, see: Drucker D.J. Exp. Opin. Invest. Drugs. 12:2003;87
10. Peters J.-U., Weber S., Kritter S., Weiss P., Wallier A., Boehringer M., Hennig M., Kuhn B., Loeffler B.-M. Bioorg. Med. Chem. Lett. 14:2004;1491
11. Measurements were performed according to an in-house developed method to assess solubility from a 10 mM DMSO stock solution. This method is similar to the classical thermodynamic shake-flask solubility with the only difference that DMSO is removed in the beginning by an additional lyophilization step. Therefore this assay is called lyophilizated solubility assay (LYSA)
12. Measurements were performed according to: Kansy M., Senner F., Gubernator K. J. Med. Chem. 41:1998;1007
13. Measurements were performed according to: Obach R.S., Baxter J.G., Liston T.E., Silber B.M., Jones B.C., MacIntyre F., Rance D.J., Wastall P. J. Pharm. Exp. Ther. 283:1997;46
14. Measurements were performed according to: Stresser D.M., Turner S.D., Blanchard A.P., Miller V.P., Crespi C.L. Drug Metab. Dispos. 30:2002;845. (BFC was used as a substrate)
15. Handrock K., Lüllmann-Rauch R., Vogt R.D. Toxicology. 85:1993;199
16. Lüllmann-Rauch R., Pods R., von Witzendorff B. Toxicology. 110:1996;27
17. Mason R.J., Walker S.R., Shields B.A., Henson J.E., Williams M.C. Am. Rev. Respir. Dis. 131:1985;786
18. Dresser G.K., Spence J.D., Bailey D.G. Clin. Pharmacokinet. 38:2000;41
19. Reasor M.J., Kacew S. Exp. Biol. Med. 226:2001;825
20. Measurements were performed according to an in-house developed miniaturized method to measure the shake flask octanol-water partition coefficient at pH 7.4 ( logD )
21. Measurements were performed according to: Allen R.I., Box K.J., Comer J., Peake C., Tam K.Y. J. Pharm. Biomed. Anal. 17:1998;699
22. An amphiphilic molecule comprises a hydrophobic and a hydrophilic part. Such molecules have an inherent tendency to orient themselves in a suitable environment, for example, a phospholipid bilayer
23. Riley R.J., Parker A.J., Trigg S., Manners C.N. Pharm. Res. 18:2001;652
24. Smith A.D., van de Waterbeemd H., Walker D.K. Mannhold R., Kubinyi H., Timmermann H. Pharmacokinetics and Metabolism in Drug Design. 2001;Wiley-VCH, Weinheim
25. Fischer, H.; Kansy, M.; Potthast, M.; Csato, M. In Proceedings of the 13th European Symposium on Quantitative Structure-Activity Relationships, Duesseldorf, Germany, Aug 27-Sept 1, 2000; Prous Science: Barcelona, Spain, 2001
26. 50 ( x ) measured for NVP-DPP728 in the assay was 11
27. Meylan W.M., Howard P.H. J. Pharm. Sci. 84:1995;83
28. Fischer H., Kansy M., Bur D. Chimia. 54:2000;640
29. Abd-Elfattah A.M, Hussain S.M., El-Reedy A.M., Yousif N.M. Tetrahedron. 39:1983;3197
30. Masquelin T., Sprenger D., Baer R., Gerber F., Mercadal Y. Helv. Chim. Acta. 81:1998;646
31. 3): δ 1.61 (2H, br s), 3.01 (3H, s), 3.23 (3H, s), 3.31 (2H, s), 3.45-3.48 (2H, m), 3.61-3.65 (2H, m), 6.70 (2H, br s), 7.38-7.40 (1H, m), 7.46-7.48 (1H, m), 7.67 (1H, s)